Article

VHL mutations predict survival of patients with renal cell carcinoma in response to the therapy of immune checkpoint inhibitors

2022-02-01

Abstract excerpt

<title>Abstract</title> <p><bold>Purpose:</bold> To identify a predictive biomarker of immune checkpoint inhibitor (ICI) therapies for renal cell carcinoma (RCC). <bold>Methods: </bold>Survival analysis of mutations in a panel of 468 cancer-related genes in a cohort of 151 RCC patients who underwent the ICI treatment using Cox regression model univariate or multivariate analysis in publicly available datasets.<bo...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: afe4abc4-0ce2-5543-8bd8-8cb316b38188
DOI: 10.21203/rs.3.rs-1291945/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

VHL mutations predict survival of patients with renal cell carcinoma in response to the therapy of immune checkpoint inhibitorsDOI 10.21203/rs.3.rs-1291945/v1Read

Development and validation of a VHL-associated immune prognostic signature for clear cell renal cell carcinomaSemantic proximity Read

VHL missense mutation delineate aggressive clear cell renal cell carcinoma subtype with favorable immunotherapeutic responseSemantic proximity Read

Current updates and future perspectives on the management of renal cell carcinoma.Semantic proximity Read

Identifying predictors of overall survival among patients with TMB-low metastatic cancer treated with immune checkpoint inhibitorsSemantic proximity Read

Sequential pathogenesis of metastatic VHL mutant clear cell renal cell carcinoma: putting it together with a translational perspective.Semantic proximity Read

Hypoxia-Inducible Factor in Renal Cell Carcinoma: From Molecular Insights to Targeted TherapiesSemantic proximity Read

Renal Cell Carcinoma Programmed Death-ligand 1, a New Direct Target of Hypoxia-inducible Factor-2 Alpha, is Regulated by von Hippel-Lindau Gene Mutation Status.Semantic proximity Read

Kidney cancer pathology in the new context of targeted therapy.Semantic proximity Read

Characterization of tumor mutation burden, PD-L1 and DNA repair genes to assess relationship to immune checkpoint inhibitors response in metastatic renal cell carcinomaSemantic proximity Read

Integrative Molecular Characterization of Sarcomatoid and Rhabdoid Renal Cell Carcinoma Reveals Determinants of Poor Prognosis and Response to Immune Checkpoint InhibitorsSemantic proximity Read

High VHL Expression Reverses Warburg Phenotype and Enhances Immunogenicity in Kidney Tumor Cells.Semantic proximity Read

High Response Rate and Durability Driven by HLA Genetic Diversity in Patients with Kidney Cancer Treated with Lenvatinib and Pembrolizumab.Semantic proximity Read